Previously, Ovoca Bio PLC invested in the second round of project investment.
The Ivix company, established in mid-2012, specializes in the development of an innovative drug based on the signal peptide BP101 — a modulator of disorders of the limbic-reticular complex to stimulate female reproductive function.
Ivix received some investments from Bioprocess Capital Ventures in 2013. In March 2019, the team completed the 3rd phase of clinical trials of the drug. In September 2019, it applied to the Ministry of Health of the Russian Federation for permission to bring the drug to the market.
The Ivix female reproductive health product is expected to go on sale by the end of 2020.
According to RVC investment director Aleksey Basov, a partnership with the Irish company Ovoca Bio PLC will accelerate the international expansion of the product.
By: Anastasia Marina.